MX2023014901A - Nanoparticulas que contienen acido nucleico. - Google Patents

Nanoparticulas que contienen acido nucleico.

Info

Publication number
MX2023014901A
MX2023014901A MX2023014901A MX2023014901A MX2023014901A MX 2023014901 A MX2023014901 A MX 2023014901A MX 2023014901 A MX2023014901 A MX 2023014901A MX 2023014901 A MX2023014901 A MX 2023014901A MX 2023014901 A MX2023014901 A MX 2023014901A
Authority
MX
Mexico
Prior art keywords
nanoparticles
nucleic acid
acid containing
containing nanoparticles
cationic lipid
Prior art date
Application number
MX2023014901A
Other languages
English (en)
Spanish (es)
Inventor
Der Meel Roy Van
Willem J M Mulder
Ewelina Kluza
Stijn Hofstraat
Tom Anbergen
Robby Cornelis Zwolsman
Henricus Marie Janssen
Pieter Michele Fransen
Original Assignee
Bio Trip B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bio Trip B V filed Critical Bio Trip B V
Publication of MX2023014901A publication Critical patent/MX2023014901A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0033—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being non-polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
MX2023014901A 2021-06-22 2022-06-22 Nanoparticulas que contienen acido nucleico. MX2023014901A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP21180786 2021-06-22
PCT/EP2022/067073 WO2022268913A1 (en) 2021-06-22 2022-06-22 Nucleic acid containing nanoparticles

Publications (1)

Publication Number Publication Date
MX2023014901A true MX2023014901A (es) 2024-04-29

Family

ID=76553579

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023014901A MX2023014901A (es) 2021-06-22 2022-06-22 Nanoparticulas que contienen acido nucleico.

Country Status (10)

Country Link
US (1) US20240216291A1 (cg-RX-API-DMAC7.html)
EP (1) EP4358936A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024526202A (cg-RX-API-DMAC7.html)
KR (1) KR20240025611A (cg-RX-API-DMAC7.html)
CN (1) CN117545467A (cg-RX-API-DMAC7.html)
AU (1) AU2022296780A1 (cg-RX-API-DMAC7.html)
CA (1) CA3222851A1 (cg-RX-API-DMAC7.html)
IL (1) IL309578A (cg-RX-API-DMAC7.html)
MX (1) MX2023014901A (cg-RX-API-DMAC7.html)
WO (1) WO2022268913A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ310613B6 (cs) 2020-09-23 2026-01-28 Ústav organické chemie a biochemie AV ČR, v. v. i. Lipidoidy pro transfekci nukleových kyselin a jejich použití
CZ310443B6 (cs) 2021-07-19 2025-06-25 Ústav organické chemie a biochemie AV ČR, v. v. i. Cyklohexanové lipidoidy pro transfekci nukleových kyselin a jejich použití
WO2023227682A1 (en) 2022-05-24 2023-11-30 Bio-Trip B.V. Modified apolipoproteins with a targeting body for lipid nanoparticles
WO2024200824A1 (en) 2023-03-29 2024-10-03 Bio-Trip B.V. Apolipoprotein lipid nanoparticle
CN117567541A (zh) * 2023-11-16 2024-02-20 中国科学技术大学 甾类阳离子脂质化合物、脂质纳米颗粒及其制备方法与应用
WO2025190968A1 (en) 2024-03-11 2025-09-18 Bio-Trip B.V. Apolipoprotein lipid nanoparticle
WO2026029597A1 (ko) * 2024-07-31 2026-02-05 주식회사 메디치바이오 신규한 스테롤 지질 또는 이의 유도체를 함유하는 지질 나노입자 조성물
GB202412885D0 (en) * 2024-09-03 2024-10-16 Imperial College Innovations Ltd Three component lipid nanoparticles
WO2026107609A1 (en) * 2024-11-25 2026-05-28 Nanovation Therapeutics Inc. Lipid nanoparticles having non-polar lipids for extrahepatic nucleic acid delivery
CN120607455B (zh) * 2025-08-06 2025-10-21 中国科学院长春应用化学研究所 可电离脂质、其立体异构体或药学上可接受的盐、制备方法和应用
CN121059567A (zh) * 2025-11-07 2025-12-05 中国医学科学院输血研究所 一种脂质纳米颗粒及其应用、药物递送载体

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4995423B2 (ja) * 2002-12-03 2012-08-08 ブランシェット・ロックフェラー・ニューロサイエンスィズ・インスティテュート 物質を血液−脳関門を渡って輸送するための人工低密度リポタンパク質キャリア
EP2217221B1 (en) * 2007-10-17 2018-06-27 Korea Advanced Institute of Science and Technology Ldl-like cationic nanoparticles for deliverying nucleic acid gene, method for preparing thereof and method for deliverying nucleic acid gene using the same
EP2279254B1 (en) 2008-04-15 2017-07-05 Protiva Biotherapeutics Inc. Novel lipid formulations for nucleic acid delivery
US8268796B2 (en) * 2008-06-27 2012-09-18 Children's Hospital & Research Center At Oakland Lipophilic nucleic acid delivery vehicle and methods of use thereof
EP2391343B1 (en) * 2009-01-29 2017-03-01 Arbutus Biopharma Corporation Improved lipid formulation for the delivery of nucleic acids
CA2754043A1 (en) * 2009-03-12 2010-09-16 Alnylam Pharmaceuticals, Inc. Lipid formulated compositions and methods for inhibiting expression of eg5 and vegf genes
WO2011044545A2 (en) * 2009-10-09 2011-04-14 Sigalov Alexander B Methods and compositions for targeted imaging
JP7330994B2 (ja) 2017-11-21 2023-08-22 アイカーン スクール オブ メディスン アット マウント サイナイ 治療用ナノ生物学的組成物による訓練免疫の促進
GB201800370D0 (en) * 2018-01-10 2018-02-21 Ucl Business Plc Anionic nanocomplexes for nucleic acid delivery
EP3947646A1 (en) * 2019-04-05 2022-02-09 Precision BioSciences, Inc. Methods of preparing populations of genetically-modified immune cells
SG11202111066UA (en) * 2019-04-26 2021-11-29 Univ Northwestern High density lipoprotein nanoparticles and rna templated lipoprotein particles for ocular therapy

Also Published As

Publication number Publication date
JP2024526202A (ja) 2024-07-17
US20240216291A1 (en) 2024-07-04
AU2022296780A9 (en) 2023-12-14
IL309578A (en) 2024-02-01
EP4358936A1 (en) 2024-05-01
AU2022296780A1 (en) 2023-12-07
CA3222851A1 (en) 2022-12-29
WO2022268913A1 (en) 2022-12-29
KR20240025611A (ko) 2024-02-27
CN117545467A (zh) 2024-02-09

Similar Documents

Publication Publication Date Title
ZA202103233B (en) Lipid nanoparticle formulations
ZA202300131B (en) Lipid nanoparticles
ZA202101465B (en) Lipid nanoparticle formulations comprising lipidated cationic peptide compounds for nucleic acid delivery
EP4635481A3 (en) Biodegradable lipids for the delivery of active agents
MX2022009018A (es) Nanoparticulas lipidas.
MX2024000327A (es) Composiciones y metodos para la administracion de arn mensajero.
WO2020051220A8 (en) Compositions and methods for organ specific delivery of nucleic acids
EP3964200A1 (en) Compositions and methods for delivery of therapeutic agents
EP4632075A3 (en) Method for reducing immunogenicity of rna
PH12020500309A1 (en) Rnai agents and compositions for inhibiting expression of angiopoietin-like 3 (angptl3), and methods of use
MX2019011004A (es) Compuestos y composiciones para la administracion intracelular de agentes terapeuticos.
MX2012014079A (es) Lipidos biodegradables para la administracion de agentes activos.
HK1250009A1 (zh) 用於将rna和水溶性治疗有效化合物递送到靶细胞的脂质颗粒制剂
BR112014018432A8 (pt) Proteína, composição imunogênica, método para produzir proteína e para tratar ou prevenir doença, molécula de ácido nucleico, vetor, célula hospedeira, uso de uma proteína, e, uso de uma composição imunogênica
MX2017015037A (es) Composiciones nutritivas que contienen un nivel elevado de inositol y usos de las mismas.
IN2015DN03219A (cg-RX-API-DMAC7.html)
EP2574170A4 (en) IMMUNOSTIMULATORY AND VACCINE COMPOSITIONS
WO2023053017A3 (en) Ionizable cationic compounds for messenger rna delivery
BRPI0417932A (pt) lipólise medicamentosa de acúmulo de gordura
ZA202403337B (en) Lipid nanoparticles for oligonucleotide delivery
WO2020097511A3 (en) Messenger rna therapy for treatment of ocular diseases
WO2020016655A3 (en) Treatment of neuropathy with dna constructs expressing igf-1 isoforms
MX341918B (es) Formulación de liposomas adecuada para tratar o prevenir la tuberculosis.
MX2025010536A (es) Nuevas formulaciones de nanoparticulas lipidicas para la administracion de acidos nucleicos
MX357071B (es) Medicamentos que comprenden apolipoproteína a-iv no glicosilada para el tratamiento de diabetes.